Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04872595 · ClinicalTrials.gov registry record · Phase 2

A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant

A Phase 2 study of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), sponsored by Memorial Sloan Kettering Cancer Center.

Active
Registry status
Phase 2
Development phase
59
Enrollment target
1
Study location

NCT04872595 is a Phase 2 study of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS) that is active but no longer recruiting, run by Memorial Sloan Kettering Cancer Center. The registered enrollment target is 59 participants, below the 143-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (59% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04872595, a Phase 2 study of Acute Myeloid Leukemia (AML) and Myelodysplastic Syndromes (MDS), is active but no longer recruiting, sponsored by Memorial Sloan Kettering Cancer Center.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
59 participants
Enrollment target
1
Study location

Study Summary

The purpose of this study is to see if conditioning regimens that include personalized rabbit ATG (P-rATG) help the immune system recover sooner and decrease the chances of transplant-related side effects. Participants in this study will be children and adults who have acute leukemia or myelodysplastic syndrome (MDS), and will receive a standard conditioning regimen to prepare the body for an allogeneic hematopoietic cell transplant (allo-HCT). The conditioning regimen will include r-ATG, one of two combinations of chemotherapy, and possibly total body irradiation (TBI).

Conditions Studied

Acute Myeloid Leukemia (AML) Myelodysplastic Syndromes (MDS) Acute Lymphoid Leukemia (ALL)

Interventions

  • DRUG Cyclophosphamide
  • DRUG Thiotepa
  • OTHER Personalized rATG (P-rATG)
  • RADIATION Hyper fractionated total body irradiation
  • DRUG GCSF

Study Locations (1)

New York

  • Memorial Sloan Kettering Cancer Center - New York

Trial Details

FieldValue
Enrollment Target 59 participants
Start Date 2021-04-30
Est. Completion 2026-04
Phase Phase 2

Sponsor

Memorial Sloan Kettering Cancer Center

1,884 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04872595

The ClinicalTrials.gov registry entry for NCT04872595 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 143-participant average among 29 other Acute Myeloid Leukemia (AML) trials with a reported enrollment target (59% lower). The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Acute Myeloid Leukemia (AML) appearing as the primary indexed condition, and to 5 interventions - of which Cyclophosphamide is the first listed.

NCT04872595 reports 1 study location spanning 1 distinct geographic area - top geographies include New York.

Frequently Asked Questions

What is clinical trial NCT04872595 about?

NCT04872595 is a clinical study titled "A Modified Dose of Rabbit Anti-thymocyte Globulin (rATG) in Children and Adults Receiving Treatment to Help Prepare Their Bodies for a Bone Marrow Transplant". The purpose of this study is to see if conditioning regimens that include personalized rabbit ATG (P-rATG) help the immune system recover sooner and decrease the chances of transplant-related side effects. Participants in this study will be children and adults who have acute leukemia or myelodysplas...

What is the current status of trial NCT04872595?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2021-04-30. Estimated completion is 2026-04.

What conditions does trial NCT04872595 study?

This clinical trial studies the following conditions: Acute Myeloid Leukemia (AML), Myelodysplastic Syndromes (MDS), Acute Lymphoid Leukemia (ALL).

What interventions are being tested in trial NCT04872595?

The interventions under investigation include: Cyclophosphamide (DRUG), Thiotepa (DRUG), Personalized rATG (P-rATG) (OTHER), Hyper fractionated total body irradiation (RADIATION), GCSF (DRUG).

Who is sponsoring clinical trial NCT04872595?

This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT04872595 being conducted?

This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Acute Myeloid Leukemia (AML)

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Acute Myeloid Leukemia (AML)

All registered trials for this condition

Myelodysplastic Syndromes (MDS)

All registered trials for this condition

New York

All trials with a study site in New York

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.